Three RTKs (c-Met, PDGFRA, and EGFR) have been reported to be targeted by miRNAs which are found to be downregulated in GBM in order to enable the upregulation of the downstream signalling which may, in turn, promote glycolytic metabolism, although it has not directly been shown. c-Met is a target of miR-410, which is downregulated in GBM compared to low WHO grade glioma and normal brain [86]. c-Met is also targeted by miR-144-3p which is downregulated in GBM [87]. The gene discussed is EGFR; the disease is glioblastoma.